Elongase genes and uses thereof
First Claim
1. An isolated nucleotide sequence corresponding to or complementary to at least about 50% of the nucleotide sequence shown in SEQ ID NO:
- 1 (FIG.
6).
0 Assignments
0 Petitions
Accused Products
Abstract
The subject invention relates to the identification of four genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. Two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of DGLA or 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ω6-docosapentaenoic acid or ω3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.
-
Citations
212 Claims
- 1. An isolated nucleotide sequence corresponding to or complementary to at least about 50% of the nucleotide sequence shown in SEQ ID NO:
-
8. A method of producing an elongase-enzyme comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
1 (FIG.
6);
b) constructing a vector comprising;
i) said isolated nucleotide sequence operably linked to ii) a promoter;
c) introducing said vector into a host cell under time and conditions sufficient for expression of said elongase enzyme. - View Dependent Claims (9, 10, 11, 12, 13, 14)
-
-
15. A vector comprising:
- a) a nucleotide sequence as represented by SEQ ID NO;
1 (FIG.
6) operably linked to b) a promoter. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 122, 123, 124, 125, 126, 127, 128)
- a) a nucleotide sequence as represented by SEQ ID NO;
- 27. A transgenic, non-human mammal whose genome comprises a DNA sequence encoding an elongase operably linked to a promoter.
-
30. A method for producing a polyunsaturated fatty acid comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
1 (FIG.
6);
b) constructing a vector comprising said isolated nucleotide sequence;
c) introducing said vector into a host cell under time and conditions sufficient for expression of elongase enzyme encoded by said isolated nucleotide sequence; and
d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 48, 49, 50, 51, 52, 53)
-
-
54. An isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:
- 2 (FIG.
22). - View Dependent Claims (55, 56, 57, 58, 59, 60)
- 2 (FIG.
-
61. A method of producing an elongase enzyme comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
2 (FIG.
22);
b) constructing a vector comprising;
i) said isolated nucleotide sequence operably linked to ii) a promoter;
c) introducing said vector into a host cell under time and conditions sufficient for expression of said elongase enzyme. - View Dependent Claims (62, 63, 64, 65, 66, 67)
-
-
68. A vector comprising:
- a) a nucleotide sequence as represented by SEQ ID NO;
2 (FIG.
22) operably linked to b) a promoter. - View Dependent Claims (69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)
- a) a nucleotide sequence as represented by SEQ ID NO;
- 80. A transgenic, non-human mammal whose genome comprises a DNA sequence, from M. alpina, encoding an elongase operably linked to a promoter.
-
83. A method for producing a polyunsaturated fatty acid comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
2 (FIG.
22);
b) constructing a vector comprising said isolated nucleotide sequence;
c) introducing said vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by said isolated nucleotide sequence; and
d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid. - View Dependent Claims (84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 101, 102, 103, 104, 105, 106)
-
-
107. An isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:
- 3 (FIG.
43). - View Dependent Claims (108, 109, 110, 111, 112, 113)
- 3 (FIG.
-
114. A method of producing an elongase enzyme comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
3 (FIG.
43);
b) constructing a vector comprising;
i) said isolated nucleotide sequence operably linked to ii) a promoter;
c) introducing said vector into a host cell under time and conditions sufficient for expression of said elongase enzyme. - View Dependent Claims (115, 116, 117, 118, 119, 120)
-
-
121. A vector comprising:
- a) a nucleotide sequence as represented by SEQ ID NO;
3 (FIG.
43) operably linked to b) a promoter. - View Dependent Claims (129, 130, 131, 132)
- a) a nucleotide sequence as represented by SEQ ID NO;
- 133. A transgenic, non-human mammal whose genome comprises a human DNA sequence encoding an elongase operably linked to a promoter.
-
136. A method for producing a polyunsaturated fatty acid comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
3 (FIG.
43);
b) constructing a vector comprising said isolated nucleotide sequence;
c) introducing said vector into a host cell under time and conditions sufficient for expression of elongase enzyme encoded by said isolated nucleotide sequence; and
d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid. - View Dependent Claims (137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159)
-
-
160. An isolated nucleotide sequence corresponding to or complementary to at least about 35% of the nucleotide sequence shown in SEQ ID NO:
- 4 (FIG.
46). - View Dependent Claims (161, 162, 163, 164, 165, 166)
- 4 (FIG.
-
167. A method of producing an elongase enzyme comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
4 (FIG.
46);
b) constructing a vector comprising;
i) said isolated nucleotide sequence operably linked to ii) a promoter;
c) introducing said vector into a host cell under time and conditions sufficient for expression of said elongase enzyme. - View Dependent Claims (168, 169, 170, 171, 172, 173)
-
-
174. A vector comprising:
- a) a nucleotide sequence as represented by SEQ ID NO;
4 (FIG.
46) operably linked to b) a promoter. - View Dependent Claims (175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)
- a) a nucleotide sequence as represented by SEQ ID NO;
- 186. A transgenic, non-human mammal whose genome comprises a DNA sequence, from C. elegans, encoding an elongase operably linked to a promoter.
-
189. A method for producing a polyunsaturated fatty acid comprising the steps of:
-
a) isolating said nucleotide sequence represented by SEQ ID NO;
4 (FIG.
46);
b) constructing a vector comprising said isolated nucleotide sequence;
c) introducing said vector into a host cell under time and conditions sufficient for expression of an elongase enzyme encoded by said isolated nucleotide sequence; and
d) exposing said expressed elongase enzyme to a substrate polyunsaturated fatty acid in order to convert said substrate to a product polyunsaturated fatty acid. - View Dependent Claims (190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212)
-
Specification